Not medical advice. This site is general information only. In an emergency call your local emergency number. For advice about your own health, speak to a doctor, pharmacist or other qualified health professional.
LEADER
About the Trial
The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results trial randomized 9,340 type 2 diabetes patients at high cardiovascular risk to the GLP-1 receptor agonist liraglutide or placebo. Liraglutide reduced major cardiovascular events by 13 percent, cardiovascular death by 22 percent, and all cause mortality by 15 percent, with reduced nephropathy. Following EMPA-REG, LEADER confirmed that diabetes drugs could deliver cardiovascular benefit. It helped establish GLP-1 agonists as cardioprotective. The drug class later produced semaglutide, whose SELECT trial showed 20 percent reduction in cardiovascular events in obesity without diabetes.
Related Trials
DCCT
The Diabetes Control and Complications Trial randomized 1,441 type 1 diabetes patients to intensive versus conventional insulin th...
UKPDS
The UK Prospective Diabetes Study followed over 5,000 newly diagnosed type 2 diabetes patients for a median of 10 years. Intensive...
ACCORD
The Action to Control Cardiovascular Risk in Diabetes trial tested intensive glucose control targeting HbA1c under 6.0 percent in ...
ADVANCE
ADVANCE randomized 11,140 type 2 diabetes patients to intensive gliclazide based glucose control or standard therapy. Intensive co...